SEC Form 4 · accession 0001209191-15-021899
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David J. Marguglio
Officer — Sr VP of Business Development · Director
Period of report
Mar 2, 2015
Accepted (ET)
Mar 3, 2015 · 8:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Mar 2, 2015 | S | 7,000 | $6.45 | D | 155,323 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.40 to $6.55, inclusive. The reporting person undertakes to provide to Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.